Navigation Links
Genomic test shows promise as chemotherapy response, survival predictor for women with breast cancer
Date:5/10/2011

HOUSTON A new genomic test combining multiple signatures a patient's estrogen receptor status, endocrine therapy response, chemotherapy resistance and sensitivity shows promise as a predictor of chemotherapy response and survival benefit in women with invasive breast cancer, according to research led by The University of Texas MD Anderson Cancer Center.

The findings, published in the May 11 issue of JAMA, also may determine those for whom standard therapy alone might not offer enough, and/or for whom an appropriate clinical trial in the adjuvant setting could provide additional benefit.

"The research builds on a decade of collaborative work in developing a clinically meaningful chemotherapy predictor, and, if validated in future studies, could guide therapy for about 80 percent of newly diagnosed women with invasive breast cancer who are candidates for chemotherapy," says W. Fraser Symmans, MD, professor in MD Anderson's Department of Pathology.

"The test helps us understand both resistance and response to chemotherapy more specifically, how sensitivity to endocrine therapy would impact a predictor and how to focus on specific subtypes of breast cancer in this case HER2 negative disease stratified by estrogen receptor (ER) status because we've learned that they are so intrinsically different," Symmans continues.

The multicenter study enrolled 310 Stage II and III newly diagnosed women with invasive breast cancer (discovery cohort). All were Her2 negative and received the chemotherapy regimen of sequential taxane and anthracycline, followed by endocrine therapy, if hormone receptor positive. Gene expression microarrays from the discovery cohort were used to develop different predictive signatures for drug resistance and response. Using the signatures for endocrine therapy response, chemotherapy resistance and sensitivity, in combination with other genomic predictors to chemotherapy response, breast cancer treatment was predicted in an independent cohort of 198 breast cancer patients with similar diagnosis and treatment (independent cohort).

The study's primary endpoint was distant relapse-free survival (DRFS) and absolute risk reduction (ARR) and the median follow up was three years. Excluding women with known endocrine sensitivity, the algorithm had a positive predictive value (PPV) of 56 percent. In the 28 percent who were predicted treatment-sensitive, their three-year DRFS was 92 percent, ARR was18 percent and they had a five-fold reduction of risk of distant relapse.

When analyzed by ER status, treatment sensitivity was predicted in 30 percent of the ER-positive women and in 26 percent of those who were ER-negative. At three year follow up, DRFS and ARR was 97 percent and 11 percent, respectively, in the ER-positive cohort, compared to 83 percent and 26 percent, respectively, in the ER-negative cohort.

"From a therapeutic standpoint, we know that the treatment a patient receives at initial diagnosis offers the greatest chance for cure. At the same time, we have many potential clinical trials with novel therapeutics and targeted agents in breast cancer. Currently, we're still not sure who we are curing with chemotherapy and who also could benefit from these novel therapies," says Lajos Pusztai, M.D., D.Phil, professor in the Department of Breast Medical Oncology and an author on the study.

If validated in future studies, these findings could be used as a treatment gatekeeper, explains Pusztai, guiding women and their physicians by affirming the selection of standard chemotherapy or, for those at greater risk for recurrence, to a potentially therapeutic clinical trial in the adjuvant setting, from which they may gain further clinical benefit.


'/>"/>

Contact: Laura Sussman
lsussman@mdanderson.org
713-745-2457
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert

Related medicine news :

1. Genomic signature in post-menopausal women may explain why pregnancy reduces breast cancer risk
2. New genomics research investigates metastatic childhood cancers
3. Promise of genomics research needs a realistic view
4. NHGRI charts course for the next phase of genomics research
5. Tufts University calls for moderate approach to teaching personalized genomic testing
6. Genomic markers may head off thousands of thyroid surgeries
7. Forces for cancer spread: Genomic instability and evolutionary selection
8. Genomic Systems announces moratorium on studying and treating terminal cancer has ended
9. La Jolla Institute to develop San Diegos first center for RNAi genomics research
10. Radiation pharmacogenomics identifies biomarkers that could personalize cancer treatment
11. St. Jude researcher receives grant to focus on cancer pharmacogenomics in children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... 2016 , ... On June 10-11, 2016, A Forever Recovery, a holistic treatment ... Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. This ... of the world’s leading providers of cereal and other breakfast foods. Its residents often ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... ... 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his ... David Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps ... in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set ... drug or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, ... traumatic event. , Trauma sufferers tend to feel a range of emotions, from depression, ...
(Date:6/24/2016)... Francisco, CA (PRWEB) , ... June 24, 2016 ... ... CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive ... self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
(Date:6/23/2016)... , June 23, 2016 , ... on Thursday, July 7, 2016 , , , , LOCATION: ... , , , , EXPERT PANELISTS:  , , , ... Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and ... The global pharmaceutical industry is witnessing an exceptional era. ...
(Date:6/23/2016)... LONDON , June 23, 2016 ... environments  Oticon , industry leaders in ... the launch of Oticon Opn ™, the world,s ... world of possibilities for IoT devices.      ... Opn, Oticon introduces a number of ,world firsts,: ...
Breaking Medicine Technology: